Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026
Change in working capital of $26.72M in Q2 FY2026
Q2 FY2026 change in working capital was $26.72M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 16.78M USD
- Year-over-year change
- —
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.78M | — |
Change in Working Capital vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 change in working capital of $16.78M is the 3rd largest of the 10 companies compared; the peer median is $247K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $84.42M | +1412.1% | +68.8% | — | |
| LTM Mar 2026 | $18.69M | +942.0% | -29.4% | 50.7% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $16.78M | — | — | — |
| LTM Mar 2026 | $15.66M | +595.3% | +26.5% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $11.65M | +1978.7% | +6.9% | — |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $10.29M | -223.3% | — | 99.7% |
| LTM Mar 2026 | $4.69M | +272.5% | -21.8% | 13022.2% | |
| LTM Mar 2026 | $3.84M | -41.3% | — | — | |
| LTM Mar 2026 | $2.99M | -169.9% | -31.7% | — | |
| LTM Jun 2026 | $247K | -98.8% | — | 3.5% | |
| Peer median (excluding KLRA) | $247K | +272.5% | -7.5% | 75.2% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (148.96M) |
| Depreciation & Amortization | 310K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 10.94M |
| Change in Working Capital | 16.78M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 4.69M |
| Other Working Capital | 12.09M |
| Other Non-Cash Items | 714K |
| Operating Cash Flow | (120.21M) |
| Capital Expenditures | (2.09M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (632.16M) |
| Sales of Investments | 141.65M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (492.6M) |
| Debt Repayment | 100M |
| Common Stock Issued | 498.97M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (499.19M) |
| Financing Cash Flow | 598.66M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | (14.15M) |
| Free Cash Flow | (122.3M) |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.